Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × aumolertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 29 Lung Neoplasms 7 Brain Neoplasms 5 Meningeal Carcinomatosis 2 Recurrence 1 Rare Tumor 1 Radiation Pneumonitis 1 Non-small Cell Lung Cancer Metastatic 1 Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1 NSCLC 1 EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor 1 Carcinoma 1 Advanced Non-small Cell Lung Cancer 1 Adenocarcinoma 1

Interventions

Oxaliplatin 42 Gemcitabine 41 Fluorouracil 37 pembrolizumab 29 Capecitabine 29 Leucovorin 26 Docetaxel 25 Cisplatin 24 Paclitaxel 21 Carboplatin 18 Bevacizumab 17 Irinotecan 16 130-nm albumin-bound paclitaxel 16 Radiotherapy 15 Pemetrexed 15 Nivolumab 13 Albumin-Bound Paclitaxel 13 Cyclophosphamide 10 Ramucirumab 9 zolbetuximab 7 Trastuzumab 7 Radiosurgery 7 Drug Therapy 7 trastuzumab deruxtecan 6 cemiplimab 6 Taxes 6 Erlotinib Hydrochloride 6 Blood Specimen Collection 6 durvalumab 5 Sorafenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Recruiting

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡